Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
Earnings Data
Report Date
Feb 10, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
0.12Last Year’s EPS
-1.39Same Quarter Last Year
Strong Buy
Based on 9 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The earnings call reflects a strong positive sentiment with significant highlights including the FDA approval of Rodemplo, robust financial performance, and substantial milestone payments indicating a successful transition to a commercial stage. However, there are some challenges in program timelines and regulatory claims that need to be addressed.Company Guidance
FDA Approval of Rodemplo
Arrowhead Pharmaceuticals announced FDA approval of Rodemplo as an adjunct to diet to reduce triglycerides in adults with familial chylomicronemia syndrome (FCS), marking its first FDA-approved medicine and transition to a commercial stage.
Robust Financial Performance
Arrowhead Pharmaceuticals reported a near breakeven result with a net loss of $2 million for fiscal year 2025, significantly improved from a net loss of $599 million in fiscal year 2024, driven by $829 million in revenue from license and collaboration agreements.
Significant Milestone Payments
The company earned a $200 million milestone payment from Sarepta and a $200 million upfront payment from Novartis for licensing collaboration agreements, along with potential future milestone payments of up to $2 billion.
Pipeline Advancements
Progress in pipeline programs including Phase III trials for Zidaziran and Aerodimer PA, and expansion into CNS with ARO MAPT for tauopathies and Alzheimer's disease, demonstrating a broad and diverse pipeline.
ARWR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
ARWR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Nov 25, 2025 | $46.79 | $57.71 | +23.34% |
Aug 07, 2025 | $16.06 | $16.42 | +2.24% |
May 12, 2025 | $13.97 | $15.28 | +9.38% |
Feb 10, 2025 | $19.92 | $18.89 | -5.17% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Arrowhead Pharmaceuticals (ARWR) report earnings?
Arrowhead Pharmaceuticals (ARWR) is schdueled to report earning on Feb 10, 2026, After Close (Confirmed).
What is Arrowhead Pharmaceuticals (ARWR) earnings time?
Arrowhead Pharmaceuticals (ARWR) earnings time is at Feb 10, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ARWR EPS forecast?
ARWR EPS forecast for the fiscal quarter 2026 (Q1) is 0.12.